Sveriges mest populära poddar
Research To Practice | Oncology Videos
Hälsa och motionMedicin

Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation (Companion Faculty Lecture)

31 min•13 februari 2023

Featuring a slide presentation and related discussion from Dr Edward Garon, including the following topics:

• Immune checkpoint inhibitor therapy for treatment-naïve advanced non-small cell lung cancer (NSCLC) without an actionable mutation (0:00)

• Duration of immunotherapy in the frontline setting for NSCLC with no targetable mutation (13:43)

• New treatment strategies for relapsed or refractory NSCLC with no targetable mutation (16:25)

• Management of antibody-drug conjugate-associated toxicity (19:08)

• Activity of antibody-drug conjugates alone or in combination with anti-PD-1 antibodies (26:18)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Visa alla avsnitt av Research To Practice | Oncology Videos
Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO
•29 min
Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH
•28 min
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD
•26 min
EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD
•30 min
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•17 min
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
•58 min
Prostate Cancer | Scott T Tagawa, MD, MS
•25 min
Prostate Cancer | Andrew J Armstrong, MD, ScM
•24 min
Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.